News
Market and company headlines
REGNAll
Loading
03:00Today1 Story
07:00-10:00Yesterday2 Stories
Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings
Regeneron (NASDAQ:REGN) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter. I think that change matters more than the market is giving it credit for. Dupixent’s Billion-Dollar Profit Drag Is Gone Last quarter, Regeneron posted non-GAAP EPS of $14.29 against an […]
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. D
03:00Yesterday1 Story
09:00Oct 231 Story
07:00-18:00Oct 212 Stories
Are You Overpaying For Regeneron Stock Versus Its Rivals?
For questions about this article or underlying research, email help@trefis.com.
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.
13:00Oct 192 Stories
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results
Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in […]
How Much Upside Is Left In Regeneron Stock?
Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.
08:00Oct 191 Story
15:00Oct 171 Story
01:00-04:00Oct 162 Stories
Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatmentOptional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a
Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?
Regeneron Pharmaceuticals reported Q2 revenue of US$4.29b, up 16.7% year on year, alongside positive 84 week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva. The data supports its recently approved use in reducing new heterotopic ossification lesions and flare ups. The 84 week OPTIMA readout suggests a sustained effect in limiting new rogue bone formation and flare ups while maintaining a generally consistent safety profile. This could reinforce...
18:00-20:00Oct 152 Stories
Regeneron Pharmaceuticals (REGN) Reports 84 Week Phase III Efficacy For FOP Treatment
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported new Phase III OPTIMA data showing Pasatru maintained efficacy out to 84 weeks in adults with FOP. The 84 week results indicate Pasatru prevented new bone formation and cut disease flare ups in treated fibrodysplasia ossificans progressiva patients. Regeneron flagged ongoing regulatory filings in additional markets and a planned pediatric trial to extend Pasatru access to younger FOP patients. The fresh 84 week Pasatru OPTIMA data fits into a...
Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds
Regeneron Pharmaceuticals (REGN) shares have been in focus after the company reported quarterly revenue of US$4.29b, up 16.7% year on year. The results beat analyst expectations and have lifted the stock about 12.4% since the release. Regeneron Pharmaceuticals has been in a strong upswing, with a 7-day share price return of 7.68% and a 90-day share price return of 17.68%. The 1-year total shareholder return of 40.63% reflects momentum that has built over time as new drug data, expanded...
13:00-18:00Oct 152 Stories
Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data
Regeneron Pharmaceuticals has seen its share price move around in recent years, and fresh trial results plus a major immunology alliance are back in focus. With the stock closing at US$778.36 and investors watching new drug data closely, the open question is whether that price still lines up with what the business earns today. Over the past 5 years, Regeneron Pharmaceuticals has delivered a total return of 39.6%, which puts real pressure on the current earnings multiple to carry that...
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.
08:00-11:00Oct 152 Stories
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and its peers.
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
Regeneron Pharmaceuticals will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.
03:00-08:00Oct 142 Stories
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.
Longleaf Partners Fund Q3 2026 Portfolio Review
The market is regaining confidence in Avantorâs ability to grow organically and in Emmanuel Lignerâs turnaround plan.
07:00-09:00Oct 132 Stories
Why A Biotech M&A Wave May Hit This Winter
Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.
Regeneron reports 84-week Phase III data for Pasatru in adult FOP
The trial showed that Pasatru prevented new heterotopic ossification lesions, compared to nine in the placebo cohort.
12:00-14:00Oct 123 Stories
Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month
The firm’s Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks.
Discover which S&P500 stocks are making waves on Monday.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control TARRYTOWN, N.Y., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week re
11:00Oct 121 Story
07:00-19:00Oct 62 Stories
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future milestone payments worth up to US$7.00 billion. These updates highlight Regeneron’s attempt to broaden its pipeline beyond current blockbusters, particularly through ubamatamab in low-grade serous ovarian cancer and next-generation long-acting immunology...
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with resectable CSCC New data explore inhibition of Factor XI for cancer-associated thrombosis, a leading cause of cancer death, where bleeding risk limits use of anticoagulants TARRYTOWN, N.Y., Oct. 06, 20
03:00Oct 61 Story
04:00Oct 41 Story
09:00-15:00Oct 22 Stories
An $8 Billion Reason Why Regeneron Stock Is in Focus
Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
08:00Oct 21 Story
07:00Oct 12 Stories
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
The agreement will see Sanofi and Regeneron co-develop and co-commercialise four long-lasting antibodies.
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.
01:00-03:00Oct 13 Stories
Sanofi, Regeneron expand partnership in deal worth up to $8 billion
Investing.com -- Sanofi SA (EPA:SASY) will pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four new long-acting medicines for inflammatory diseases, as the French drugmaker looks to build its pipeline beyond its blockbuster Dupixent treatment.
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share dev
05:00-11:00Sep 292 Stories
REGN or ILMN: Which Is the Better Value Stock Right Now?
REGN vs. ILMN: Which Stock Is the Better Value Option?
Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...
03:00-05:00Sep 292 Stories
RBC Capital Reiterates Sector Perform on Regeneron Pharmaceuticals, Maintains $737 Price Target
RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and maintains $737 price target.
What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?
Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...
09:00-14:00Sep 283 Stories
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
The healthcare company will release its third-quarter results next month.
Why This Regeneron Eye Rival Just Catapulted More Than 120%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
07:00Sep 281 Story
15:00Sep 221 Story
04:00Sep 201 Story
09:00-12:00Sep 182 Stories
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV delivery systems, precision medicine investment, and expanding clinical pipelines for genetic disorders, oncology, cardiovascular and neurological diseases. North America leads the market, while Asia-Pacific is expected to grow fastest. Key players include CRISPR Therapeut
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
09:00-11:00Sep 172 Stories
Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight
Until 2007, paroxysmal nocturnal hemoglobinuria (PNH) was a life-threatening disorder with limited therapeutic options for controlling hemolysis and thrombosis, the latter being a major contributor to mortality. The treatment landscape underwent a significant transformation with the introduction of the anti-C5 complement inhibitor eculizumab, which substantially reduced hemolysis, lowered transfusion requirements, and, importantly, decreased the risk of thrombosis.
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
11:00-15:00Sep 42 Stories
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
00:00Sep 41 Story
07:00-09:00Sep 22 Stories
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron Pharmaceuticals has a market
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.
